An examination of sleep spindle metrics in the Sleep Heart Health Study: superiority of automated spindle detection over total sigma power in assessing age-related spindle decline.

Drug development EEG Sigma Coherence Sigma Power Sleep Spindles Spindle coherence

Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
06 Oct 2023
Historique:
received: 06 07 2022
accepted: 08 09 2023
medline: 9 10 2023
pubmed: 7 10 2023
entrez: 6 10 2023
Statut: epublish

Résumé

Sleep spindle activity is commonly estimated by measuring sigma power during stage 2 non-rapid eye movement (NREM2) sleep. However, spindles account for little of the total NREM2 interval and therefore sigma power over the entire interval may be misleading. This study compares derived spindle measures from direct automated spindle detection with those from gross power spectral analyses for the purposes of clinical trial design. We estimated spindle activity in a set of 8,440 overnight electroencephalogram (EEG) recordings from 5,793 patients from the Sleep Heart Health Study using both sigma power and direct automated spindle detection. Performance of the two methods was evaluated by determining the sample size required to detect decline in age-related spindle coherence with each method in a simulated clinical trial. In a simulated clinical trial, sigma power required a sample size of 115 to achieve 95% power to identify age-related changes in sigma coherence, while automated spindle detection required a sample size of only 60. Measurements of spindle activity utilizing automated spindle detection outperformed conventional sigma power analysis by a wide margin, suggesting that many studies would benefit from incorporation of automated spindle detection. These results further suggest that some previous studies which have failed to detect changes in sigma power or coherence may have failed simply because they were underpowered.

Sections du résumé

BACKGROUND BACKGROUND
Sleep spindle activity is commonly estimated by measuring sigma power during stage 2 non-rapid eye movement (NREM2) sleep. However, spindles account for little of the total NREM2 interval and therefore sigma power over the entire interval may be misleading. This study compares derived spindle measures from direct automated spindle detection with those from gross power spectral analyses for the purposes of clinical trial design.
METHODS METHODS
We estimated spindle activity in a set of 8,440 overnight electroencephalogram (EEG) recordings from 5,793 patients from the Sleep Heart Health Study using both sigma power and direct automated spindle detection. Performance of the two methods was evaluated by determining the sample size required to detect decline in age-related spindle coherence with each method in a simulated clinical trial.
RESULTS RESULTS
In a simulated clinical trial, sigma power required a sample size of 115 to achieve 95% power to identify age-related changes in sigma coherence, while automated spindle detection required a sample size of only 60.
CONCLUSIONS CONCLUSIONS
Measurements of spindle activity utilizing automated spindle detection outperformed conventional sigma power analysis by a wide margin, suggesting that many studies would benefit from incorporation of automated spindle detection. These results further suggest that some previous studies which have failed to detect changes in sigma power or coherence may have failed simply because they were underpowered.

Identifiants

pubmed: 37803266
doi: 10.1186/s12883-023-03376-3
pii: 10.1186/s12883-023-03376-3
pmc: PMC10557170
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

359

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Nat Hum Behav. 2021 Jan;5(1):123-145
pubmed: 33199858
Psychopharmacology (Berl). 2001 Sep;157(3):299-304
pubmed: 11605086
Biol Rev Camb Philos Soc. 2021 Jun;96(3):1021-1034
pubmed: 33533183
Anesthesiology. 2014 Nov;121(5):978-89
pubmed: 25187999
Eur Neuropsychopharmacol. 2016 Oct;26(10):1649-56
pubmed: 27554636
Sleep Med. 2020 Nov;75:37-44
pubmed: 32853916
Neuropsychopharmacology. 2012 Apr;37(5):1224-33
pubmed: 22237311
J Psychopharmacol. 2012 Aug;26(8):1081-7
pubmed: 22057018
Physiol Rev. 2020 Apr 1;100(2):805-868
pubmed: 31804897
J Psychopharmacol. 2010 Nov;24(11):1613-8
pubmed: 19487320
Sleep. 2014 Oct 01;37(10):1609-19
pubmed: 25197807
Sleep Med. 2016 Mar;19:93-100
pubmed: 27198953
Sleep. 2013 Feb 01;36(2):259-67
pubmed: 23372274
Nat Methods. 2014 Apr;11(4):385-92
pubmed: 24562424
Neuropsychopharmacology. 1999 Sep;21(3):455-66
pubmed: 10457543
Neuropsychopharmacology. 2005 Apr;30(4):833-41
pubmed: 15602499
Nat Rev Neurosci. 2010 Feb;11(2):114-26
pubmed: 20046194
Sleep. 2013 Sep 01;36(9):1369-76
pubmed: 23997371
J Am Med Inform Assoc. 2018 Oct 1;25(10):1351-1358
pubmed: 29860441
Am J Psychiatry. 2007 Mar;164(3):483-92
pubmed: 17329474
Sleep. 1997 Dec;20(12):1077-85
pubmed: 9493915
Lancet Neurol. 2003 Mar;2(3):167-76
pubmed: 12849238
Sleep. 2021 Apr 9;44(4):
pubmed: 33165618
Sci Data. 2020 Jun 19;7(1):190
pubmed: 32561751
J Sleep Res. 2012 Dec;21(6):612-9
pubmed: 22591117
PLoS One. 2016 Feb 22;11(2):e0149770
pubmed: 26901503
Neuroimage. 2014 Oct 1;99:103-10
pubmed: 24852461
Front Hum Neurosci. 2015 Jun 24;9:353
pubmed: 26157375
J Clin Sleep Med. 2011 Oct 15;7(5):493-501A
pubmed: 22003345
J Neurosci Methods. 2015 Aug 15;251:37-46
pubmed: 25956566
Sleep Med Rev. 2003 Oct;7(5):423-40
pubmed: 14573378
Biol Psychiatry. 2012 Jan 15;71(2):154-61
pubmed: 21967958
Psychopharmacology (Berl). 1997 Apr;130(3):285-91
pubmed: 9151364
Brain. 2005 May;128(Pt 5):1049-61
pubmed: 15705609
J Neurosci. 2013 Mar 6;33(10):4494-504
pubmed: 23467365
Elife. 2021 Oct 14;10:
pubmed: 34648426
Neurobiol Aging. 2015 Feb;36(2):1083-90
pubmed: 25442116
Sleep Med. 2011 Feb;12(2):134-41
pubmed: 21256805
Sleep. 2007 May;30(5):593-602
pubmed: 17552374
Nat Commun. 2017 Jun 26;8:15930
pubmed: 28649997
Front Neurosci. 2013 Dec 26;7:267
pubmed: 24431986
J Sleep Res. 2006 Sep;15(3):250-5
pubmed: 16911026

Auteurs

Kalyan Palepu (K)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.

Kolia Sadeghi (K)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.

Dave F Kleinschmidt (DF)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.

Jacob Donoghue (J)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.

Seth Chapman (S)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.

Alexander R Arslan (AR)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.

M Brandon Westover (MB)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.
Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, 02215, USA.

Sydney S Cash (SS)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA.
Clinical Data Animation Center (CDAC), Massachusetts General Hospital, 50 Staniford Street, Fruit St, Boston, MA, 02114, USA.

Jay Pathmanathan (J)

Beacon Biosignals, 22 Boston Wharf Rd 7th Floor, Suite 41, Boston, MA, 02210, USA. jay.pathmanathan@beacon.bio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH